OC patients with low risk score had a higher PD1&CTLA4 immunophenoscore, higher TMB score, higher HLA-related genes, lower TIDE score, lower tumor escape score and lower immune checkpoints expression, suggesting TRPS as an indicator for predicting immunotherapy benefit. The gene discussed is CTLA4; the disease is neoplasm.